InnoCare Pharma (9969) Schedules Board Meeting for Third-Quarter 2025 Results

Bulletin Express

2025/10/31

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited disclaim any responsibility for the announcement’s contents, accuracy, or completeness.

InnoCare Pharma Limited (the “Company,” stock code: 9969) has scheduled a board meeting on Thursday, 13 November 2025 to consider and approve the unaudited results of the Company and its subsidiaries for the nine months ended 30 September 2025, along with related matters concerning the publication of those results. The announcement is dated 31 October 2025.

As of the date of the announcement, the board of directors comprises Chairperson and Executive Director, Dr. Jisong Cui; Executive Director, Dr. Renbin Zhao; Non-executive Directors, Dr. Yigong Shi and Mr. Ronggang Xie; and Independent Non-executive Directors, Ms. Lan Hu, Dr. Dandan Dong, and Prof. Kunliang Guan.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1110866784"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110866784\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110866784?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 17:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110866784","market":"hk","top_or_hot":-1,"title":"InnoCare Pharma (9969) Schedules Board Meeting for Third-Quarter 2025 Results","media":"Bulletin Express","content":"<p>Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited disclaim any responsibility for the announcement’s contents, accuracy, or completeness.</p>\n<p>InnoCare Pharma Limited (the “Company,” stock code: 9969) has scheduled a board meeting on Thursday, 13 November 2025 to consider and approve the unaudited results of the Company and its subsidiaries for the nine months ended 30 September 2025, along with related matters concerning the publication of those results. The announcement is dated 31 October 2025.</p>\n<p>As of the date of the announcement, the board of directors comprises Chairperson and Executive Director, Dr. Jisong Cui; Executive Director, Dr. Renbin Zhao; Non-executive Directors, Dr. Yigong Shi and Mr. Ronggang Xie; and Independent Non-executive Directors, Ms. Lan Hu, Dr. Dandan Dong, and Prof. Kunliang Guan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InnoCare Pharma (9969) Schedules Board Meeting for Third-Quarter 2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoCare Pharma (9969) Schedules Board Meeting for Third-Quarter 2025 Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2025-10-31 17:22</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited disclaim any responsibility for the announcement’s contents, accuracy, or completeness.</p>\n<p>InnoCare Pharma Limited (the “Company,” stock code: 9969) has scheduled a board meeting on Thursday, 13 November 2025 to consider and approve the unaudited results of the Company and its subsidiaries for the nine months ended 30 September 2025, along with related matters concerning the publication of those results. The announcement is dated 31 October 2025.</p>\n<p>As of the date of the announcement, the board of directors comprises Chairperson and Executive Director, Dr. Jisong Cui; Executive Director, Dr. Renbin Zhao; Non-executive Directors, Dr. Yigong Shi and Mr. Ronggang Xie; and Independent Non-executive Directors, Ms. Lan Hu, Dr. Dandan Dong, and Prof. Kunliang Guan.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09969","symbol_name":"諾誠健華","start_time":0,"source_url":"","article_id":"1110866784","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110866784","pubTimestamp":1761902568,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited disclaim any responsibility for the announcement’s contents, accuracy, or completeness. InnoCare Pharma Limited...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09969":"诺诚健华"},"translate_title":"诺诚健华医药(9969)安排董事会会议公布2025年第三季度业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09969":1},"content_text":"Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited disclaim any responsibility for the announcement’s contents, accuracy, or completeness.\nInnoCare Pharma Limited (the 「Company,」 stock code: 9969) has scheduled a board meeting on Thursday, 13 November 2025 to consider and approve the unaudited results of the Company and its subsidiaries for the nine months ended 30 September 2025, along with related matters concerning the publication of those results. The announcement is dated 31 October 2025.\nAs of the date of the announcement, the board of directors comprises Chairperson and Executive Director, Dr. Jisong Cui; Executive Director, Dr. Renbin Zhao; Non-executive Directors, Dr. Yigong Shi and Mr. Ronggang Xie; and Independent Non-executive Directors, Ms. Lan Hu, Dr. Dandan Dong, and Prof. Kunliang Guan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}